ArticlePloS one2026
Study protocol for a double-blinded randomized clinical trial evaluating effectiveness of neurodynamic approach in lower limb for diabetic peripheral sensory neuropathy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic peripheral sensory neuropathy (DPSN) presents with pain or neuropathy symptoms and disturbances in lower limb sensory functions, leading to complicated diabetic foot conditions and declining quality of life. There is a research gap on the non-pharmacological conservative approach to this disabling condition. The objective of this study is to evaluate the effectiveness of the neurodynamic approach, along with electrophysical stimulation, in reducing the severity of neuropathic symptoms and improving the quality of life in patients with DPSN.
methodsAn assessor and patient-blinded randomized clinical trial (RCT) on 90 DPSN cases through hospital-based simple random sampling. Participants will be randomly assigned equally to either the Neurodynamic approach or the Sham neurodynamic approach group by concealed allocation between April and August 2025 at the Nurul Islam Diabetic Center in Jashore, Bangladesh. The experimental group will receive the Neurodynamic approach, and the control group will receive the sham approach; however, both groups will receive transcutaneous electrical nerve stimulation (TENS) and home exercises for 12 sessions over 4 weeks. A pretest will be taken at baseline, a posttest after 4 weeks, and a follow-up evaluation after 12 weeks. In addition to outcome measures, manageable and fatal adverse events will be documented and reported. DISCUSSION: This trial will be implemented in the non-pharmacological management of prevalent cases with DPSN and diabetic foot, sparing the burden of polypharmacy in people living with diabetes. Moreover, a positive result may guide clinicians toward an alternative in evidence-based practice, especially in a low-resource country like Bangladesh. This single-center trial may be limited by a lack of external generalizability, but it will lead to multicenter, large-sample studies in the future.
trial registrationRegistered from Clinical Trial Registry of India CTRI/2025/01/079801 [Registered on: 30/01/2025] Trial Registered Prospectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.